SRT 003
Alternative Names: SRT-003Latest Information Update: 31 Mar 2025
At a glance
- Originator San Rocco Therapeutics
- Class Antihypertensives; Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiovascular disorders; Pulmonary arterial hypertension
Most Recent Events
- 25 Mar 2025 Preclinical trials in Cardiovascular disorders in USA (Parenteral) prior to March 2025 (San Rocco Therapeutics Pipeline, March 2025)
- 25 Mar 2025 Preclinical trials in Pulmonary arterial hypertension in USA (Parenteral) prior to March 2025 (San Rocco Therapeutics Pipeline, March 2025)